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additional studies, but factors other than bacterial
virulence are probably more important in the
development of a symptomatic UTI into USB.
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ABSTRACT
Isolates of Escherichia coli from 31 Norwegian and
31 Russian females with signiﬁcant bacteruria
who presented with clinical signs of urinary tract
infection (UTI) were tested for antimicrobial
sensitivity, the presence of virulence genes, phy-
logroup distribution and clonal afﬁnity. Twenty
isolates, representing the full clonal diversity of a
collection of 138 intestinal isolates of E. coli from
healthy Norwegian females, served as a reference
group. Russian UTI isolates belonged more often
to phylogroup A and possessed fewer virulence
genes than did Norwegian isolates. UTI isolates of
E. coli were genetically heterogeneous and had a
high degree of antimicrobial sensitivity.
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Escherichia coli is an important component of the
normal intestinal ﬂora of humans and other
mammals [1]. E. coli is also the predominant
cause of urinary tract infection (UTI) in humans of
all age groups worldwide [2,3]; indeed, > 80% of
community-acquired UTI is caused by E. coli [4,5].
Some clones of UTI-associated E. coli seem to be
globally distributed [6]. E. coli strains fall into four
main phylogenetic groups: A, B1, B2 and D.
Pathogenic extra-intestinal isolates are reported to
belong mainly to groups B2 and D, which have
been shown to possess higher numbers of viru-
lence genes than do phylogroups A and B1 [7,8].
The aim of the present study was to compare the
genetic and phenotypic characteristics of E. coli
isolates from Norwegian and Russian females
with UTI to determine whether they differed in
terms of clonality, phylogroup distribution, viru-
lence or sensitivity to antimicrobial agents.
E. coli were collected from two groups of
patients with signiﬁcant bacteruria (pure culture
of ‡ 10 000 bacteria ⁄mL): (i) 31 Russian females
with clinical symptoms of UTI (complicated and
uncomplicated cystitis and UTI in pregnancy;
mean age 24 years, range 17–32 years); and (ii) 31
non-hospitalised Norwegian females (mean age
35 years, range 16–56 years) with uncomplicated
UTI who were selected randomly from females
included in a previous study [5]. A reference
group of 138 intestinal isolates of E. coli from ten
healthy Norwegian females (mean age 52 years,
range 51–55 years) with a normal diagnosis in a
colonoscopy screening programme [9] was also
included. A subset of this group, representing 20
separate clones identiﬁed by pulsed-ﬁeld gel
electrophoresis (PFGE), was selected for investi-
gation in this study.
E. coli was identiﬁed by colony morphology
and biochemical proﬁle using the three tube test
[10]. Sensitivity to ten antibiotics (Table 1) was
determined using Etests (AB Biodisk, Solna,
Sweden). The presence of extended-spectrum
b-lactamases (ESBLs) was determined using 10-
lg cefpodoxime disks with and without 1 lg
Table 1. Characteristics of uropath-
ogenic and intestinal isolates of
Escherichia coli
Russiana
(n = 31)
Norwegianb
(n = 31)
Intestinalc
(n = 20)
n % n % n %
Sensitivity (breakpoint mg ⁄L)
Ampicillin (£ 0.5) 0 0 0 0 0 0
Mecillinam (£ 2) 29 94 28 90 20 100
Gentamicin (£ 2) 31 100 30 97 20 100
Chloramphenicol (£ 8) 27 87 29 94 18 90
Tetracycline (£ 4) 4 13 1 3 6 30
Ciproﬂoxacin (£ 0.5) 31 100 31 100 20 100
Nalidixic acid (£ 16) 31 100 30 97 19 95
Nitrofurantoin (£ 32) 30 97 30 97 20 100
Sulphonamide (£ 64) 12 39 10 32 12 60
Trimethoprim (£ 2) 24 77 26 84 18 90
Phylogenetic group
A 17 55 2 6 6 30
B1 0 0 3 10 5 25
B2 7 23 14 45 3 15
D 7 23 12 39 6 30
Gene (virulence factor)
ﬁmA (type 1 ﬁmbriae) 27 87 31 100 20 100
sfaD ⁄E (S ﬁmbriae) 10 32 8 26 1 5
papC (P ﬁmbriae) 15 48 24 77 14 70
papG-I (class I) 0 0 0 0 1 5
papG-II (class II) 4 13 9 29 1 5
papG-III (class III) 4 13 9 29 0 0
draA (Dr haemagglutinin) 7 23 13 42 3 15
neuB (capsule K1) 4 13 9 29 2 10
kﬁC (capsule K5) 5 16 2 6 3 15
iutA (aerobactin) 16 52 12 39 8 40
hlyA (haemolysin) 8 26 12 39 4 20
Total 100 129 57
Median number ⁄ isolate 3 4 2
aRussian females with clinical symptoms of urinary tract infection.
bNorwegian females with uncomplicated urinary tract infection.
cRepresentative clones of intestinal isolates from ten healthy Norwegian females.
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clavulanic acid (AB Biodisk). Breakpoints were
as recommended by The Norwegian Working
Group on Antibiotics (http://www.antibiotika-
resistens.no). E. coli ATCC 25922 was used as a
quality control strain. PFGE was performed as
described previously [11]. XbaI restriction pat-
terns were compared using GelCompar software
(Applied Maths, Sint-Martens-Latem, Belgium).
The presence of 11 virulence genes (Table 1) was
investigated using three sets of multiplex PCR
assays [12]. Phylogroup determination was per-
formed using a two-step triplex PCR [13].
Phylogroup distributions and the presence of
virulence factors were compared using Fisher’s
exact test. The MIC values and number of
virulence factors were compared using the Krus-
kal–Wallis test and the Mann–Whitney U-test.
Analyses were performed using Statistica soft-
ware (Statsoft Inc., Tulsa, OK, USA). All tests
were two-tailed with a 95% signiﬁcance level.
With the exception of ampicillin, tetracycline
and sulphonamide, the antimicrobial sensitivity
(% sensitive) was high in all groups, but was
highest among the reference isolates from healthy
females (Table 1). None of the isolates expressed
ESBLs, and Norwegian and Russian isolates of
E. coli from UTI were more sensitive than isolates
from several other countries [4]. There were no
signiﬁcant differences in the distribution of MICs
between the Russian and Norwegian groups of
UTI isolates. Relative to UTI isolates, the MICs of
ampicillin, tetracycline, sulphonamide and
ciproﬂoxacin for the reference intestinal isolates
tended towards signiﬁcantly lower values.
Apart from two Russian isolates with identical
PFGE band patterns, phylogenetic group and
virulence proﬁles, all UTI isolates had band
patterns differing by more than six bands. Rus-
sian isolates belonged mainly to phylogroup A
(Table 1). Phylogroups B2 and D were predom-
inant among the Norwegian UTI isolates; only
two were of phylogroup A. Norwegian UTI
isolates had a signiﬁcantly higher number of
virulence genes than did Russian isolates and
intestinal isolates (Table 1). Signiﬁcantly more
Norwegian UTI isolates contained the P-ﬁmbriae
gene than did Russian isolates. Comparing across
groups, the B2 phylogroup isolates had higher
numbers of virulence factors than did isolates in
the other phylogroups. There was no correlation
between the presence of virulence factors and
antimicrobial resistance, although the low rate of
resistance would make such an association difﬁ-
cult to detect among these isolates.
The high rates of sensitivity to antimicrobial
agents that were found in both Russian and
Norwegian isolates may be explained by the low
consumption of antibiotics in these countries,
resulting in low selection pressure. Antibiotic use
is not monitored in Russia, but a comparatively
low level of antibiotic use has been reported [14].
Consumptionof antibiotics inNorway remains low
(17.2 deﬁned daily doses ⁄ 1000 inhabitants ⁄year)
(http://www.antibiotikaresistens.no). Except for
the two Russian isolates that were identical, all
isolates differed by more than six PFGE bands
and probably represented different clones [15].
Virulent extra-intestinal strains of E. coli belong
mainly to phylogroups B2 or D, whereas com-
mensal strains belong predominantly to groups A
and B1 [7,8]. Norwegian UTI isolates conformed
to this pattern, but E. coli isolates from Russia
were associated less with phylogroups B2 and D,
and most isolates belonged to phylogroup A.
Russian phylogroup A isolates might be more
virulent than phylogroup A isolates from Nor-
way, and were very similar in virulence proﬁle to
the phylogroup A isolates of the international
ECOR study [16] (data not shown). Alternatively,
the two groups may not be strictly comparable, as
the Russian isolates were from patients with a
greater range of clinical conditions who belonged
to a younger age group.
Strains from phylogroups A and B1 have been
found to preferentially infect compromised hosts
[17], and are associated with speciﬁc blood group
antigens and the non-secretor phenotype [18].
These factors have not been evaluated in this
study. Finally, it should be noted that Norway
currently enjoys better general socioeconomic
conditions than Russia, and the possibility that
this plays a role in predisposition to UTI cannot
be excluded.
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ABSTRACT
Linezolid is not yet recognised as a standard
therapy for infective endocarditis. This report
describes nine patients with endocarditis treated
with linezolid and 33 similar cases from the
medical literature. The majority of cases in-
volved multiresistant strains, and the reasons
for administering linezolid were refractory
disease (60%), intolerance (28%), sequential
therapy (12%) and a resistant pathogen (1%).
Linezolid was administered for a mean of
37 days, with a successful outcome in 79% of
cases. Reversible adverse effects were described
in ten cases. The mean follow-up period was
8.5 months. Further data from randomised con-
trolled clinical trials are needed to determine
the efﬁcacy and safety of linezolid for treating
endocarditis.
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